The business agreement, signed today by SPL Medical and NanoEcho, is a comprehensive contract. The agreement grants NanoEcho exclusivity regarding the supply of ferumoxtran (iron oxide-based nanoparticles) for use in magnetomotive ultrasound.
Learn more in the press release.
Related news items
Radboudumc Investment Day keeps growing
11 October 2024Scientists, entrepreneurs and investors from the life sciences & health sector came together to exchange knowledge, network and talk about new collaborations.
read moreThird Radboudumc Investment Day again well-attended
16 October 2023On October 12, the Radboudumc Investment Day took place for the third time. Scientists, entrepreneurs and investors from the life sciences & health sector came together in the Radboudumc Experience Center to exchange knowledge, network and talk about new collaborations.
read moreThirona Raises €7,5 Million New Financing
14 September 2023Nijmegen, the Netherlands (September 11th, 2023) – Thirona, a global company specialized in advanced analysis of thoracic CT images with artificial intelligence and Radboudumc spin-off, is thrilled to announce the successful completion of its new investment.
read moreThirona awarded to receive EIC grant
30 June 2023Following the second 2023 EIC Accelerator cut-off in March, Thirona is awarded to receive European Innovation Council (EIC) funding.
read moreBoosting the startup ecosystem in Nijmegen!
22 June 2023TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.
read moreSPL Medical announces collaboration with NanoEcho for application of Ferrotran® (Ferumoxtran) for Ultrasound detection of Lymph node metastases
30 September 2022SPL medical and NanoEcho have signed a Letter of Intent and initiated a cooperation on regulatory partnership and supply for SPL medical proprietary iron-based nanoparticle Ferrotran® (Ferumoxtran) product and platform.
read more